Archives
WASHINGTON, April 6, 2006 — The pharmaceutical industry, which mounted a huge lobbying campaign to thwart attempts by states to reduce drug prices, also has spent tens of millions of dollars on campaign contributions and fights over ballot initiatives, a Center for Public Integrity analysis of state campaign funds has found. >>
WASHINGTON, April 6, 2006 — Pursuing average savings of 25 percent to 50 percent below U.S. prices, many states have defied the federal government and turned to countries such as Canada for access to affordable prescription drugs for their citizens. >>
WASHINGTON, March 30, 2006 — Through an apparent loophole in agency rules the Food and Drug Administration has allowed its employees to receive more than $1.3 million in sponsored travel since 1999 from groups closely tied to pharmaceutical and medical device companies. >>
Special Report
WASHINGTON, July 7, 2005 — The pharmaceutical and health products industry has spent more than $800 million in federal lobbying and campaign donations at the federal and state levels in the past seven years, a Center for Public Integrity investigation has found. >>
WASHINGTON, July 7, 2005 — Thalomid is a popular treatment for a progressive blood disease known as multiple myeloma—a cancer of the plasma cells that is responsible for more than 10,000 deaths annually in the United States. The drug accounted for more than three-quarters of the $377 million in revenue generated last year by its manufacturer, New Jersey-based Celgene Corp. In fact, the global pharmaceutical company's Web site proclaims that Thalomid is "the current driver of Celgene revenue growth." >>
WASHINGTON, July 7, 2005 — Chances are, the commercial is familiar, seen more often than not at dinnertime: a middle-aged woman begins a discussion by saying, "I can't even believe I'm talking about this." >>
WASHINGTON, July 7, 2005 — The pharmaceutical and health products industry has given nearly $150 million to federal and state candidates and parties, along with some political non-profits, in the last four election cycles, a Center for Public Integrity analysis of campaign finance records revealed. Sixty-five percent, or almost $100 million, went to Republicans. >>
July 7, 2005 — Here's what the pharmaceutical industry has gotten on its political investment: >>
WASHINGTON, July 1, 2005 — The Pharmaceutical Research and Manufacturers of America, which represents 67 parent companies and subsidiaries that develop and make prescription and over-the-counter drugs, listed contacts with the government's top officials overseeing international trade agreements on more lobbying reports than it did for contacts with the Food and Drug Administration, which directly oversees the industry's products. >>
WASHINGTON, January 18, 2005 — The U.S. pharmaceutical industry, which is mounting a multi-million dollar campaign to prevent importation of prescription drugs from across the northern borders, enlisted an ex-envoy to Canada and his former top aide to lobby the government with which they once conducted diplomacy, Canadian lobbying disclosure records reviewed by the Center for Public Integrity revealed. >>